BICYCLE THERAPEUTICS PLC
BCYC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCYC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCYC
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on its proprietary Bicycle® technology, with a focus on oncology and targeted radioligand therapies. As of June 30, 2026, the company reported cash and equivalents of $510.1M and a net loss of $50.3M for the quarter [sec].
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 2 clinical trials for BICYCLE THERAPEUTICS PLC.
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on its proprietary Bicycle® technology, with a focus on oncology and targeted radioligand therapies. As of June 30, 2026, the company reported cash and equivalents of $510.1M and a net loss of $50.3M for the quarter [sec].
- Cash and equivalents of $510.1M as of June 30, 2026, with shareholders' equity of $668.9M and total debt of $0.6M [sec].
- The company is advancing two lead product candidates: nuzefatide pevedotin and BT1702 [sec_mda · as of 2026-07-30].
- In March 2026, Bicycle announced cost-saving initiatives and a strategic reprioritization expected to decrease near-term expenses and capital requirements [sec_mda · as of 2026-07-30].
- The company has an accumulated deficit of $879.6 million as of the most recent reporting period, reflecting ongoing research and development costs [sec_mda · as of 2025-10-30].
- A private placement completed in May 2024 is expected to extend the cash runway into the second half of 2027 [sec · filed 2025-04-23].
What works
- Strong cash position of $510.1M as of June 30, 2026, with minimal debt of $0.6M, providing a multi-year runway into the second half of 2027 [sec] [sec · filed 2025-04-23].
- Proprietary Bicycle® technology platform enables the development of novel therapeutics with potential advantages in tissue penetration and target binding [sec_mda · as of 2026-07-30].
- Strategic reprioritization in March 2026 is expected to reduce near-term expenses and focus resources on highest-potential programs [sec_mda · as of 2026-07-30].
What to weigh
- The company has an accumulated deficit of $879.6 million and continues to report net losses ($50.3M in Q2 2026 alone), with no approved products generating revenue [sec_mda · as of 2025-10-30] [sec].
- All product candidates are in clinical or preclinical stages, and the company expects to incur significant expenses and operating losses for the foreseeable future [sec_mda · as of 2026-07-30].
- Dependence on successful clinical development and regulatory approval of lead candidates nuzefatide pevedotin and BT1702, which are still in early-to-mid-stage trials [sec_mda · as of 2026-07-30].
From the filings
Quoted directly from source documents.
Private placement completed in May 2024 extends cash runway into second half of 2027
“successfully completing the Private Placement in May 2024, which is expected to extend our cash runway into the second half of 2027”
SEC filings · April 23, 2025
Accumulated deficit of $879.6 million
“of $879.6 million. These losses have resulted primarily from costs incurred in connection with research and development activities”
SEC MD&A · October 30, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Total revenue of only $0.6M in Q2 2026, with no approved products generating commercial sales [sec].
- Clinical development uncertainty
- Accumulated deficit and ongoing losses — Accumulated deficit of $879.6M and net loss of $50.3M in Q2 2026, with expectations of continued losses [sec_mda · as of 2025-10-30] [sec].
- Dependence on cost-saving measures — Near-term expense reduction depends on successful execution of March 2026 strategic reprioritization [sec_mda · as of 2026-07-30].
What to watch
- Clinical data readouts for nuzefatide pevedotin and BT1702, which are the company's lead product candidates [sec_mda · as of 2026-07-30].
- Cash burn rate and whether the $510.1M cash position extends beyond the second half of 2027 as projected [sec] [sec · filed 2025-04-23].
- Progress of the strategic reprioritization announced in March 2026 and its impact on operating expenses and pipeline focus [sec_mda · as of 2026-07-30].
- Any new partnerships or licensing deals that could provide non-dilutive funding or validate the Bicycle platform [sec_mda · as of 2026-07-30].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BICYCLE THERAPEUTICS PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BICYCLE THERAPEUTICS PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
32.0 months
D/E 0.19 · 0% dilution
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
0 buys · 22 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$131.4M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 10,885,357 | $50.5M |
| fcpm iii services b.v. | 3,468,430 | $16.1M |
| armistice capital, llc | 3,398,000 | $15.8M |
| principal financial group inc | 1,174,625 | $5.5M |
| renaissance technologies llc | 979,300 | $4.5M |
| morgan stanley | 618,327 | $2.9M |
| schroder investment management group | 615,833 | $2.7M |
| diadema partners lp | 476,424 | $2.2M |
| birchview capital, lp | 463,599 | $2.2M |
| silvercrest asset management group llc | 428,684 | $2.0M |
Showing top 10 of 94 institutional holders of BICYCLE THERAPEUTICS PLC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.8%
- Days to cover
- 4.5
- Shares short
- 2,635,218
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCYC short interestGovernance
Frequently asked questions
What is the AI investment thesis for BICYCLE THERAPEUTICS PLC?
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on its proprietary Bicycle® technology, with a focus on oncology and targeted radioligand therapies. As of June 30, 2026, the company reported cash and equivalents of $510.1M and a net loss of $50.3M for the quarter [sec].
What is BICYCLE THERAPEUTICS PLC's lead drug candidate?
BICYCLE THERAPEUTICS PLC's most advanced tracked candidate is BT5528 (Phase 2) for Advanced Solid Tumor Historically Known for High EphA2 Expression.
Who is the CEO of BICYCLE THERAPEUTICS PLC?
Dr. Kevin Lee M.B.A., Ph.D. is the chief executive officer of BICYCLE THERAPEUTICS PLC (BCYC).
Where is BICYCLE THERAPEUTICS PLC headquartered?
BICYCLE THERAPEUTICS PLC (BCYC) is headquartered in Cambridge, United Kingdom.
What therapeutic areas does BICYCLE THERAPEUTICS PLC focus on?
BICYCLE THERAPEUTICS PLC develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.